The European Medicines Agency on Thursday approved an update to the product information for Novo Nordisk A/S’ (NYSE:NVO) Wegovy, enabling the weight management drug to be delivered at controlled temperatures of up to 30°C for as long as 48 hours.

The decision marks a shift away from strict cold chain requirements and positions Wegovy as the first GLP-1 therapy in Europe with this level of delivery flexibility.

Novo Nordisk Reduced Cold Chain Dependency

Previously, Wegovy distribution relied entirely on cold chain logistics, requiring consistent refrigeration from manufacturing to patient use.

With the revised guidance, the final stage of delivery—from pharmacies to patients—can now occur within a 48-hour window without refrigeration, provided temperatures do not exceed 30°C.

This change is expected to ...